Literature DB >> 7611714

Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome.

S R Levine1, R L Brey, K L Sawaya, L Salowich-Palm, J Kokkinos, B Kostrzema, M Perry, S Havstad, J Carey.   

Abstract

We prospectively studied 81 consecutively identified patients with antiphospholipid antibodies (aPLs) who developed focal cerebral ischemia over a 7-year period. The mean age of this cohort was approximately a decade younger than the average atherothromboembolic stroke victim and women were more commonly involved than men. The frequency of conventional stroke risk factors was lowest in the group of stroke patients with the highest levels of IgG cardiolipin immunoreactivity. Other serological abnormalities associated with aPL (false-positive Venereal Disease Research Laboratory test, thrombocytopenia, prolonged activated partial thromboplastin time [aPTT]) were more common in the group with over 100 GPL units (high positive). Patients with the highest IgG anticardiolipin titers had the shortest times to subsequent thrombo-occlusive events. The most common recurrent event was cerebral infarction, often occurring within the first year of follow-up during a mean prospective follow-up of 3 years. Over one-half of the cohort had at least one recurrent thrombo-occlusive event during follow-up. This distinct syndrome of cerebral ischemia should be recognized for its younger age at onset, predominance of women, high risk of recurrent thrombo-occlusive events, and the possible use of the IgG anticardiolipin antibody titer for prognosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7611714     DOI: 10.1002/ana.410380119

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  12 in total

1.  Antiphospholipid Antibody Syndrome.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-09       Impact factor: 3.598

Review 2.  Antiphospholipid antibodies in young adults with stroke.

Authors:  Robin L Brey
Journal:  J Thromb Thrombolysis       Date:  2005-10       Impact factor: 2.300

Review 3.  Neurologic manifestations of the antiphospholipid syndrome.

Authors:  D Tanne; S Hassin-Baer
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

Review 4.  Lupus vasculitis: differential diagnosis with antiphospholipid syndrome.

Authors:  Theo Dov Golan
Journal:  Curr Rheumatol Rep       Date:  2002-02       Impact factor: 4.592

5.  Evoked potential studies in the antiphospholipid syndrome: differential diagnosis from multiple sclerosis.

Authors:  D Paran; J Chapman; A D Korczyn; O Elkayam; O Hilkevich; G B Groozman; D Levartovsky; I Litinsky; D Caspi; Y Segev; V E Drory
Journal:  Ann Rheum Dis       Date:  2005-08-17       Impact factor: 19.103

6.  Study on relationship between anticardiolipin antibody and cerebrovascular diseases.

Authors:  C Liu; Y Xia; S Sun; G Yuan; E Tong
Journal:  J Tongji Med Univ       Date:  1999

Review 7.  Antiphospholipid syndrome and vascular ischemic (occlusive) diseases: an overview.

Authors:  Penka A Atanassova
Journal:  Yonsei Med J       Date:  2007-12-31       Impact factor: 2.759

Review 8.  Manipulation of coagulation factors in acute stroke.

Authors:  J F Meschia; J Biller
Journal:  Drugs       Date:  1997       Impact factor: 9.546

Review 9.  Screening for hypercoagulable syndromes following stroke.

Authors:  Cheryl Bushnell; Larry B Goldstein
Journal:  Curr Atheroscler Rep       Date:  2003-07       Impact factor: 5.113

10.  Prevalence and isotype distribution of antiphospholipid antibodies in unselected Chilean patients with venous and arterial thrombosis.

Authors:  Iván Palomo; Jaime Pereira; Marcelo Alarcón; Marcela Vásquez; Carmen Pinochet; María T Vélez; Jorge Sandoval; Gloria Icaza; Silvia Pierangeli
Journal:  Clin Rheumatol       Date:  2004-01-31       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.